The increasing budgetary constraints faced by healthcare payers have made the access decision increasingly complex and decentralized processes a growing trend. Thus, demonstration of new health technologies value has become critical to ensure patients’ access to innovation. OBJECTIVES: To identify the most important value messages within decision making process in the treatment of Type 2 Diabetes Mellitus (T2DM) among General Practitioners (GP) coordinating Primary Care Centers. METHODS: Regional meetings based on Health Economics training held (during 2013) with GPs, including the presentation of a cost-effectiveness analysis of vildagliptin vs sulphonilureas (SU) and a budget impact tool that enables the estimation of meaningful impacts of T2DM. Two surveys were developed to be applied at beginning and end of training to characterize the learning insights and identify the factors considered in the decision process. RESULTS: Partial results based on a 51 GPs sample are presented. The positive impact of the training in HE concepts was statistically significant (p=0.000) with an 89.4% average rate of correct answers. More than 50% of GPs considered the increasing prevalence of T2DM, cost of macrovascular and microvascular complications and the impact of hipoglycaemias in patients’ quality of life (QoL) and costs, as the most important factors in the decision process. The key decision factor to use vildagliptin is the improvement of patients’ QoL. The use of SU is explained due to its fast response, mainly in patients with Hb1Ac level above 7.5%. Majority of GPs (87.5%) chose vildagliptin as the preferred therapeutic for T2DM patients not controlled with metformin. CONCLUSIONS: This analysis demonstrated that both epidemiological and economic factors are important at local decision process. Clinically, patients’ QoL is the most relevant achievement. Most GPs prefer vildagliptin to control T2DM, considering QoL improvements its greatest benefit.